Use of ChemoFx® for Identification of Effective Treatments in Epithelial Ovarian Cancer

Richard, Scott D.; Wells, Alan; Price, Fredric V.

doi:10.1371/currents.eogt.8b0b6fffc7b999b34bc4c8152edbf237

Cited by 9 publications

(9 citation statements)

References 29 publications

(51 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This innovative technology looks to overcome CSC chemotherapy resistance occurring in some cancers, and to prevent recurrence. Randomized, assay-directed clinical trials are currently ongoing against glioblastoma and epithelial ovarian cancer, with overall response rate as primary outcome measure (ClinicalTrials.gov numbers: NCT03632798, NCT03949283 and NCT03632798); The ChemoFX ® assay has been developed by the US company Helomics and is dedicated to gynaecological cancers 36 . Its endpoint is total DNA quantification.…”

Section: State-of-the-art: Assays Showing Significant Predictive Capacitiesmentioning

confidence: 99%

See 1 more Smart Citation

Benefits of functional assays in personalized cancer medicine: more than just a proof-of-concept

et al. 2021

View full text Add to dashboard Cite

As complex and heterogeneous diseases, cancers require a more tailored therapeutic management than most pathologies. Recent advances in anticancer drug development, including the immuno-oncology revolution, have been too often plagued by unsatisfying patient response rates and survivals. In reaction to this, cancer care has fully transitioned to the “personalized medicine” concept. Numerous tools are now available tools to better adapt treatments to the profile of each patient. They encompass a large array of diagnostic assays, based on biomarkers relevant to targetable molecular pathways. As a subfamily of such so-called companion diagnostics, chemosensitivity and resistance assays represent an attractive, yet insufficiently understood, approach to individualize treatments. They rely on the assessment of a composite biomarker, the ex vivo functional response of cancer cells to drugs, to predict a patient's outcome. Systemic treatments, such as chemotherapies, as well as targeted treatments, whose efficacy cannot be fully predicted yet by other diagnostic tests, may be assessed through these means. The results can provide helpful information to assist clinicians in their decision-making process. We explore here the most advanced functional assays across oncology indications, with an emphasis on tests already displaying a convincing clinical demonstration. We then recapitulate the main technical obstacles faced by researchers and clinicians to produce more accurate, and thus more predictive, models and the recent advances that have been developed to circumvent them. Finally, we summarize the regulatory and quality frameworks surrounding functional assays to ensure their safe and performant clinical implementation. Functional assays are valuable in vitro diagnostic tools that already stand beyond the “proof-of-concept” stage. Clinical studies show they have a major role to play by themselves but also in conjunction with molecular diagnostics. They now need a final lift to fully integrate the common armament used against cancers, and thus make their way into the clinical routine.

show abstract

Section: State-of-the-art: Assays Showing Significant Predictive Capacitiesmentioning

confidence: 99%

“…The ChemoFX ® assay has been developed by the US company Helomics and is dedicated to gynaecological cancers 36 . Its endpoint is total DNA quantification.…”

Section: State-of-the-art: Assays Showing Significant Predictive Capacitiesmentioning

confidence: 99%

Benefits of functional assays in personalized cancer medicine: more than just a proof-of-concept

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Such an approach formed the basis for early chemosensitivity assays using patient cells. 69,70 The use of more precise analytical methods, such as high-content imaging, to identify specifically the subpopulations of cells that are sensitive or resistant to drug treatment may require the creative generation of novel drug response evaluation criteria to correlate in vitro drug response with clinical efficacy. [71][72][73][74] In summary, we have made significant advances to an unprecedented level to model cancer with much greater accuracy for precision medicine, in moving from the use of simplistic monolayer culture methods to the use of primary tumor sources and sophisticated 3D systems.…”

Section: Development Of New Approaches To Assess Cellular Response Inmentioning

confidence: 99%

3D Culture as a Clinically Relevant Model for Personalized Medicine

Fong

Toh

et al. 2017

SLAS Technology

View full text Add to dashboard Cite

Advances in understanding many of the fundamental mechanisms of cancer progression have led to the development of molecular targeted therapies. While molecular targeted therapeutics continue to improve the outcome for cancer patients, tumor heterogeneity among patients, as well as intratumoral heterogeneity, limits the efficacy of these drugs to specific patient subtypes, as well as contributes to relapse. Thus, there is a need for a more personalized approach toward drug development and diagnosis that takes into account the diversity of cancer patients, as well as the complex milieu of tumor cells within a single patient. Three-dimensional (3D) culture systems paired with patient-derived xenografts or patient-derived organoids may provide a more clinically relevant system to address issues presented by personalized or precision medical approaches. In this review, we cover the current methods available for applying 3D culture systems toward personalized cancer research and drug development, as well as key challenges that must be addressed in order to fully realize the potential of 3D patient-derived culture systems for cancer drug development. Greater implementation of 3D patient-derived culture systems in the cancer research field should accelerate the development of truly personalized medical therapies for cancer patients.

show abstract

“…The ChemoFX assay utilizes a differential staining readout technique using DAPI staining combined with automated quantification of viable cells in 2D. Several prospective studies have been reported, which showed an increase in overall survival of 14 months using assay‐directed treatment for 262 ovarian cancer patients . In a smaller study using breast cancer biopsies, pathological complete response correlated with assay outcome in vitro and was found to achieve a sensitivity of 83.3% and 71.4% specificity .…”

Section: The Functional Approach: Chemoresponse Assaysmentioning

confidence: 99%

Bringing 3D tumor models to the clinic – predictive value for personalized medicine

Halfter¹,

Mayer

2017

Biotechnology Journal

View full text Add to dashboard Cite

Current decision-guiding algorithms in cancer drug treatment are based on decades of research and numerous clinical trials. For the majority of patients, this data is successfully applied for a systemic disease management. For a number of patients however, treatment stratification according to clinically based risk criteria will not be sufficient. The most effective treatment options are ideally identified prior to the start of clinical drug therapy. This review will discuss the implementation of three-dimensional (3D) cell culture models as a preclinical testing paradigm for the efficacy of clinical cancer treatment. Patient tumor-derived cells in 3D cultures duplicate the individual tumor microenvironment with a minimum of confounding factors. Clinical implementation of such personalized tumor models requires a high quality of methodological and clinical validation comparable to other biomarkers. A non-systematic literature search demonstrated the small number of prospective studies that have been conducted in this area of research. This may explain the current reluctance of many physicians and insurance providers in implementing this type of assay into the clinical diagnostic routine despite potential benefit for patients. Achieving valid and reproducible results with a high level of evidence is central in improving the acceptance of preclinical 3D tumor models.

show abstract

Use of ChemoFx® for Identification of Effective Treatments in Epithelial Ovarian Cancer

Cited by 9 publications

References 29 publications

Benefits of functional assays in personalized cancer medicine: more than just a proof-of-concept

Benefits of functional assays in personalized cancer medicine: more than just a proof-of-concept

3D Culture as a Clinically Relevant Model for Personalized Medicine

Bringing 3D tumor models to the clinic – predictive value for personalized medicine

Contact Info

Product

Resources

About